avibactam sodium; aztreonam · Abbvie · NDA 217906
Emblaveo
Earliest generic entry, as listed
7 Feb 2033
Blocked by exclusivity: GAIN.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8969566 | substance | 15 Jun 2032 |
| US 9284314 | substance | 15 Jun 2032 |
| US 9695122 | substance, product | 15 Jun 2032 |
| US 8471025 | substance | 12 Aug 2031 |
| US 8835455 | product | 8 Oct 2030 |
| US 7612087 | product | 12 Nov 2026 |
Exclusivities · 2 unexpired
| GAIN | qualified infectious disease product | 7 Feb 2033 |
| NP | new product | 7 Feb 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217906 · 001 · RLD | powder, intravenous | EQ 0.5GM BASE/VIAL;1.5GM/VIAL | 7 Feb 2033 |
Expired or delisted (1)
- US 7112592 · substance, product, use U-4147 · 7 Jan 2026